News & Views | Published:

Targeting RAS and PI3K in lung cancer

Nature Medicine volume 14, pages 13151316 (2008) | Download Citation

Subjects

The phosphoinositide 3-kinase (PI3K) and RAS oncoproteins are activated in many major tumor types and control linked signaling pathways. An inhibitor of PI3K is now shown to shrink tumors in transgenic mouse cancer models. The drug also blocks RAS-induced lung tumors when combined with an inhibitor of mitogen-activated protein kinase kinase (pages 1351–1356).

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Nat. Rev. Cancer 3, 11–22 (2003).

  2. 2.

    , , & Biochim. Biophys. Acta 1784, 159–185 (2008).

  3. 3.

    et al. Nat. Med. 14, 1351–1356 (2008).

  4. 4.

    et al. Science 304, 554 (2004).

  5. 5.

    et al. Mol. Cancer Ther. 7, 1851–1863 (2008).

  6. 6.

    et al. Cell 129, 957–968 (2007).

  7. 7.

    & Cancer Cell 8, 381–392 (2005).

  8. 8.

    et al. Mol. Cancer Ther. 6, 2209–2219 (2007).

  9. 9.

    et al. Cancer Cell 4, 437–450 (2003).

Download references

Author information

Affiliations

  1. Julian Downward is at the Cancer Research UK London Research Institute, 44 Lincoln's Inn Fields, London WC2A 3PX, UK.  downward@cancer.org.uk

    • Julian Downward

Authors

  1. Search for Julian Downward in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm1208-1315

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing